PT - JOURNAL ARTICLE AU - Aguilar, Jacob B. AU - Faust, Jeremy Samuel AU - Westafer, Lauren M. AU - Gutierrez, Juan B. TI - Investigating the Impact of Asymptomatic Carriers on COVID-19 Transmission AID - 10.1101/2020.03.18.20037994 DP - 2020 Jan 01 TA - medRxiv PG - 2020.03.18.20037994 4099 - http://medrxiv.org/content/early/2020/03/26/2020.03.18.20037994.short 4100 - http://medrxiv.org/content/early/2020/03/26/2020.03.18.20037994.full AB - Coronavirus disease 2019 (COVID-19) is a novel human respiratory disease caused by the SARS-CoV-2 virus. Asymptomatic carriers of the virus display no clinical symptoms but are known to be contagious. Recent evidence reveals that this sub-population, as well as persons with mild and undocumented disease, represent a major contributor in the propagation of this disease. However, this method of transmission frequently escapes detection by public health surveillance systems. Because of this, the currently accepted estimates of the basic reproduction number (ℛ0) of the virus are inaccurate. Further, it is unlikely that a pathogen can blanket the planet in three months with an ℛ0 in the vicinity of 3, as reported (1–6). In this manuscript, we present a mathematical model taking into account asymptomatic and other undocumented carriers. Our results indicate that an initial value of the effective reproduction number could range from 5.5 to 26.5. Results from the first three weeks of the model exhibit exponential growth, which is in agreement with average case data collected from thirteen countries with universal health care and robust communicable disease surveillance systems; the average rate of growth in the number of reported cases is 23.3% per day during this period.Competing Interest StatementThe authors have declared no competing interest.Funding StatementN/AAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in this article is available from public sources. https://tinyurl.com/USA-COVID-19-Cases https://drive.google.com/open?id=18qaRKnQG1GoXamnzJwkHu2GG9xCe4w8_